Danish pharmaceutical company Novo Nordisk is moving into the complex and more expensive business of inventing new forms of insulin, which would bring it closer to the riskier drug-discovery activities of the wider pharmaceutical industry.
from WSJ.com: US Business http://ift.tt/2dS44Sq
via IFTTT
No comments:
Post a Comment